Dermatologist care tied to better self-detection of melanoma

Dermatologist care tied to better self-detection of melanoma

(HealthDay)—Patients with self-detected primary melanoma who have an established dermatologist are more likely to have thinner lesions at the time of diagnosis, according to research published in the May issue of the Journal of the American Academy of Dermatology.

Michelle Y. Cheng, of the University of Pittsburgh School of Medicine, and colleagues conducted a retrospective cross-sectional study of 388 patients with primary to assess the association between the characteristics of dermatologic care and melanoma depth at diagnosis.

The researchers found that patients with an established , compared with those without an established dermatologist, were more likely to receive a diagnosis of melanoma in situ (63.6 versus 44.5 percent; P = 0.001) and have thinner invasive melanoma (0.48 versus 0.61 mm; P = 0.003). These patterns were observed for patients with self-detected, but not dermatologist-detected, melanoma. Self-detected melanomas were in situ for 59.0 percent of with an established dermatologist, compared with 37.0 percent of those without an established dermatologist (P = 0.006). Melanoma invasiveness or depth was not related to time from last dermatologic examination or wait time for an appointment.

"Education obtained at the dermatology appointment may improve early self-detection of melanoma, and having an established dermatologist may facilitate earlier evaluation of concerning lesions," the authors write.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

AAD: Older men should screen themselves for skin cancer

Mar 01, 2013

(HealthDay)—Men aged 50 years or older are more likely to be diagnosed with invasive melanoma by a dermatologist than to detect it themselves; and they are less likely to seek a skin cancer screening due ...

Stage III/IV melanoma patients at risk for new primaries

Dec 10, 2013

(HealthDay)—Patients with stage III or IV melanoma who have not received treatment with BRAF inhibitors remain at risk for developing new primary melanomas (NPMs), although the incidence rates are lower ...

Recommended for you

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.